175 INNOVATION BOULEVARD, WILMINGTON, DE
Investor Presentation
Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Announces Exclusive Option Agreement to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Other Events
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload